Delcath Systems announced that subgroup analyses from its phase 3 FOCUS study of the FDA-approved HEPZATO KIT for unresectable metastatic uveal melanoma were published in the Journal of Cancer ...

The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing ...

Delcath Systems (DCTH) announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication was published in the Journal of Cancer Research and Clinical Oncology.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...

Efforts to improve reporting clinical trial results have led to the development of guidelines such as those recommended by the CONSORT group. 3,4 Transparent and comprehensive reporting of subgroup ...

Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...

Claims of differential treatment effects were largely rated as “low credibility” or “very low credibility.” Subgroup analyses in cancer trials may not be credible, and their results should be ...

This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma A total of 221 publications reporting data on ...